PRECISION CAPITAL
ADVANCING
PRECISION HEALTH

A PURPOSE-BUILT VENTURE FIRM

We combined accomplished investment professionals and operators with a proprietary national medical network platform to create the most unique venture firm in life sciences. MEC deploys precision capital to nurture and advance the precision health innovations that solve the biggest, most complex medical problems.

Proprietary Network of the World’s Leading Physician Scientists >
Team of Experienced VCs, Company Creators and Operators >

MEDICAL EXCELLENCE CAPITAL

A Differentiated Early-Stage Life Sciences Venture Fund >

ADVANCING THE PRECISION HEALTH DECADE

At MEC, we believe the technologies created in this decade will lead to a golden age in innovation within the life sciences space. MEC invests in company creation, seed, Series A, and Series B opportunities where technology and novel approaches are transformative for patient care and directly address large, unmet needs. Our areas of focus include, but are not limited to:

AI TO
ADVANCE DRUG
DISCOVERY
CELL AND GENE THERAPY
PRECISION MEDICINE
REGENERATIVE MEDICINE
SYNTHETIC BIOLOGY

OUR PORTFOLIO

Immunitas Therapeutics
Active
Nobias Therapeutics
Active
ProJenX
Active
Rejuvitas
Active
View All

NEWS & BLOG

View the latest posts and investment news from MEC.

Press Release
Immunitas Therapeutics Appoints Seng-Lai ‘Thomas’ Tan, Ph.D. as Chief Scientific Officer
Read More
Blog Post
2021 Year to Date Update
Read More
Press Release
Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases
Read More
View All

TAKE THE NEXT STEP

Contact us today for more information about MEC.

GET IN TOUCH